Press Release Mar 18 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Apalutamide Tablets, which are indicated for treating metastatic castration-sensitive prostate cancer. The tablets will be manufactured at Zydus Lifesciences Ltd's facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 16 2025
- Press Release Mar 14 2025
- Press Release Mar 12 2025
- Press Release Mar 10 2025
- Press Release Mar 05 2025
Later from Zydus Lifesciences
- Press Release Apr 11 2025
- Press Release Apr 16 2025
- Press Release Apr 17 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
- Press Release Apr 25 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences